E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial

Detalles Bibliográficos
Autores principales: Bewersdorf, Jan Philipp, Stahl, Maximilian, Taylor, Justin, Mi, Xiaoli, Chandhok, Namrata Sonia, Watts, Justin, Derkach, Andriy, Wysocki, Mateusz, Lu, Sydney X., Bourcier, Jessie, Hogg, Simon J., Rahman, Jahan, Chaudhry, Sana, Totiger, Tulasigeri M., Abdel-Wahab, Omar, Stein, Eytan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681888/
https://www.ncbi.nlm.nih.gov/pubmed/37814121
http://dx.doi.org/10.1038/s41375-023-02050-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681888/
https://www.ncbi.nlm.nih.gov/pubmed/37814121
http://dx.doi.org/10.1038/s41375-023-02050-4

Ejemplares similares